Citations

Clear

1134 citation(s) found for "Li, Yan".

Clinical Characteristics and Computed Tomography Findings in Adult Patients With an Aberrant Right Subclavian Artery: A Single-Center Retrospective Cohort Study
Valery, Jose R. , Bi, Yan , Alsafi, Wail, Bakhit, Mohamed, Shaikheldin, Ahmed , Grage, Rolf A. , Stowell, Justin T. , Cid, Omar J., White, Launia J. , Sonavane, Sushilkumar K. , White, Launia, Cortés, Pedro , Harris, Dana M. , Stancampiano, Fernando F. , Bakhit, Mohamed, Cid, Omar, Heckman, Michael G.

Mayo Clinic

Journal of Computer Assisted Tomography | February 2, 2023 | Volume: 47 | Issue: 3 | Pages: 382-389

10.1097/rct.0000000000001435 | PMID 37185000 Get It

Objective We sought to determine the prevalence and possible features associated with symptoms in adult patients diagnosed with an aberrant right subclavian artery (ARSA). Methods In this single-center retrospective study, 386 adult patients were diagnosed with ARSA on chest CT scans performed between June 2016 and April 2021. Patients were grouped by the presence of symptoms, which included dysphagia, shortness of breath, cough, and upper airway wheezing. Four cardiothoracic radiologists reviewed the chest CT scans to assess features of ARSA. Agreement and multivariable logistic regression analyses were performed to determine interobserver variability and features associated with the presence of symptoms, respectively. Results The prevalence of ARSA was 1.02% and 81.3% of patients were asymptomatic. Shortness of breath (74.6%) was the most common symptom. Interobserver agreement was acceptable with most variables having an interclass correlation coefficient or κ >0.80. A patient's height > 158 cm (OR: 2.50, P = 0.03), cross-sectional area > 60 mm2 of ARSA at the level of the esophagus (OR: 2.39, P = 0.046), and angle >108 degrees formed with the aortic arch (OR: 1.99, P = 0.03) were associated with the presence of symptoms on multivariable logistic regression. A distance increase per 1 mm between ARSA and trachea (OR: 0.85, P = 0.02) was associated with decreased odds of symptoms. Conclusions Aberrant right subclavian artery is an incidental finding in most adult patients. The cross-sectional area at the level of the esophagus, angle formed with the medial wall of the aortic arch, distance between the ARSA and the trachea, and a patient's height were features associated with the presence of symptoms.
Artificial Intelligence for Evaluation of Emotions behind Face Masks
Boonipat, Thanapoom , Bite, Uldis, Yan, María

Mayo Clinic

Plastic & Reconstructive Surgery | January 25, 2023 | Volume: 151 | Issue: 2 | Pages: 354e-356e

10.1097/prs.0000000000009878 | PMID 36696347 Get It

Guideline compliance and outcomes of genetic testing in pancreatic cancer patients.
Hardway, Heather D , Starr, Jason S. , Riegert‐Johnson, Douglas L. , Potjer, Thomas P. , Bi, Yan , Klatte, Derk C.F. , Hardway, Heather , Clift, Kristin , Leerdam, Monique E. van , Presutti, R. John , Wallace, Michael B.

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 688-688

10.1200/jco.2023.41.4_suppl.688 Get It

688 Background: Guidelines recommend patients with pancreatic ductal adenocarcinoma (PDAC) undergo genetic testing for germline pathogenic variants (PV). The aim of this study was to evaluate compliance with recently updated guidelines (May 2019) and assess subsequent uptake and outcomes of genetic testing in PDAC patients. In addition, social and clinical factors associated with genetic testing were assessed. Methods: A retrospective chart review of patients diagnosed with PDAC between May 2018 and August 2020 was performed. Discussion and subsequent uptake of genetic testing was reviewed and compared between a 12-month period before (pre-guideline) and a 12-month period after (post-guideline) guidelines were updated, accounting for a three-month transition period. Univariate and multivariate logistic regression analysis was used to assess factors predictive of undergoing genetic testing. Results: In total, 534 patients with PDAC were identified; 321 (60.1%) in the pre-guideline period and 213 (39.9%) in the post-guideline period. The mean age at diagnosis was 68 years and 47% were female. Genetic testing was discussed in 34% (109/321) of pre-guideline and in 39% (84/213) of post-guideline patients ( P = .23). Of those, 82% (89/109) of patients in pre-guideline and 75% (63/84) in post-guideline groups underwent subsequent genetic testing ( P = .71). In 26 (17.1%) of 152 tested patients, a PV was identified, of which 17 (11.2%; 17/152) had a PDAC-associated PV. Age, cancer stage at diagnosis, length of survival, and having a first-degree relative with pancreatic cancer were significant predictors of genetic testing on multivariate analysis. Conclusions: Adherence to recently updated guidelines is poor and germline genetic testing in PDAC patients remains insufficient. Efforts to increase awareness of benefits of testing, which include personalized therapies for patients and cascade testing in family members for subsequent enrollment in pancreatic cancer surveillance programs, could improve future uptake.[Table: see text]
Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.
Haimi, Ido, Dettwyler, Shenin A. , Bi, Yan , Chung, Daniel C. , Farrell, James J. , Kastrinos, Fay , Klute, Kelsey , Sussman, Daniel A. , Zogopoulos, George , Everett, Jessica N. , Brand, Randall E. , Grossberg, Aaron J. , Katona, Bryson W , Kupfer, Sonia S. , Lucas, Aimee Lee , Paiella, Salvatore , Parmigiani, Giovanni , Permuth, Jennifer B. , Sears, Rosalie C. , Simeone, Diane M.

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 689-689

10.1200/jco.2023.41.4_suppl.689 Get It

689 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer typically discovered at incurable stages. The PRECEDE Consortium was established to accelerate early detection by using a large-scale, collaborative, innovative model, predicated on standardized collection of demographic, clinical, and imaging data from high-risk individuals (HRI). Here we report the initial pancreas imaging findings in Cohort 1, representing HRI with familial pancreatic cancer (FPC) or pathogenic germline variants (PGV) in PDAC susceptibility genes with a 1 st or 2 nd degree relative with PDAC. Methods: The PRECEDE Consortium (NCT04970056) began enrollment in 5/2020. HRI enrolled prospectively at centers worldwide into one of 7 cohorts based on personal and/or family history of PDAC and PGV status. PRECEDE’s planned enrollment is 10,000 patients. Data sharing is required to join PRECEDE, facilitated by a standardized data collection system and central database (PRECEDELink). Imaging (MRI/MRCP and EUS) is performed using standardized image acquisition and reporting templates. Imaging and clinical sequencing data are stored and analyzed in the PRECEDE data cloud. Results: By 9/16/2022, 26 sites enrolled 3156 patients in 7 cohorts, with 1716 in Cohort 1. Cohort 1 was 60% female, 80% white; 48% met FPC criteria, and 52% were PGV carriers. Within Cohort 1, 658 FPC and 965 PGV (1353 total, 79%) underwent imaging (68% MRI; 32% EUS). Overall, 573/1353 (42%) had pancreas abnormalities: 320/573 (49%) FPC, and 253/573 (36%) PGV (OR [95% CI] 1.65 [1.32–2.06], P < 0.001). Cysts were the most common abnormality, present in 549/1353 (41%) and accounting for 310/320 (97%) FPC and 239/253 (94%) PGV HRI abnormalities. Of 549 HRI with cysts, 262 (48%) had 1 cyst, including 137/310 (44%) FPC and 125/239 (52%) PGV HRI (OR 1.43 [1.07–1.92], P = .012) The remaining 287/549 (52%) had ≥2 cysts, including 173/310 (56%) FPC and 114/239 (48%) PGV HRI (OR 1.98 [1.49–2.64], P < 0.001). Worrisome features occurred in 83/1353 (6.1%) including: 14 (1%) cyst > 2 cm, 7 (0.5%) cyst ≥3 cm, 35 (2.6%) main pancreatic duct (MPD) diameter ≥5 mm; 2 (0.15%) duct strictures; and 25 (1.8%) solid masses. Solid masses included 1 (0.07%) PDAC, 9 (0.7%) neuroendocrine tumors, and 15 (1.1%) benign lesions (e.g. lipoma, splenule). Conclusions: Pancreatic abnormalities are common in a cohort of 1353 HRI enrolled in PRECEDE; 6.1% of HRI had findings with worrisome features and clinical implications. Multiple cysts were significantly more common in FPC HRI (OR 1.98); worrisome findings did not differ between FPC and PGV groups. The longitudinal study of this growing HRI cohort with standardized imaging and matched comprehensive epidemiological, clinical, and laboratory data, along with germline testing, will provide critical information and understanding of PDAC risk, and augment existing clinical decision-making models governing surveillance and treatment.
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
Barham, Whitney , Hsu, Michelle A. , Liu, Xin , Harrington, Susan M. , Hirdler, Jacob B. , Gicobi, Joanina K. , Zhu, Xingxing , Zeng, Hu , Pavelko, Kevin D. , Yan, Yiyi , Hsu, Michelle, Mansfield, Aaron S , Dong, Haidong , Pavelko, Kevin D , Zeng, Hu , Zhu, Xingxing , Mansfield, Aaron S. , Dong, Haidong

Mayo Clinic

ImmunoHorizons | January 19, 2023 | Volume: 7 | Issue: 1 | Pages: 125-139

10.4049/immunohorizons.2200054 | PMID 36656137 Get It

Abstract Seven different anti–PD-1 and PD-L1 mAbs are now widely used in the United States to treat a variety of cancer types, but no clinical trials have compared them directly. Furthermore, because many of these Abs do not cross-react between mouse and human proteins, no preclinical models exist in which to consider these types of questions. Thus, we produced humanized PD-1 and PD-L1 mice in which the extracellular domains of both mouse PD-1 and PD-L1 were replaced with the corresponding human sequences. Using this new model, we sought to compare the strength of the immune response generated by Food and Drug Administration–approved Abs. To do this, we performed an in vivo T cell priming assay in which anti–PD-1/L1 therapies were given at the time of T cell priming against surrogate tumor Ag (OVA), followed by subsequent B16-OVA tumor challenge. Surprisingly, both control and Ab-treated mice formed an equally robust OVA-specific T cell response at the time of priming. Despite this, anti–PD-1/L1-treated mice exhibited significantly better tumor rejection versus controls, with avelumab generating the best protection. To determine what could be mediating this, we identified the increased production of CX3CR1+PD-1+CD8+ cytotoxic T cells in the avelumab-treated mice, the same phenotype of effector T cells known to increase in clinical responders to PD-1/L1 therapy. Thus, our model permits the direct comparison of Food and Drug Administration–approved anti–PD-1/L1 mAbs and further correlates successful tumor rejection with the level of CX3CR1+PD-1+CD8 + T cells, making this model a critical tool for optimizing and better utilizing anti–PD-1/L1 therapeutics.
Extracellular vesicle‑mediated miR‑126‑3p transfer contributes to inter‑cellular communication in the liver tumor microenvironment
Moirangthem, Anuradha, Gondaliya, Piyush , Sayyed, Adil Ali , Driscoll, Julia , Yan, Irene K. , Ali Sayyed, Adil , Patel, Tushar

Mayo Clinic

International Journal of Oncology | January 16, 2023 | Volume: 62 | Issue: 2 | Pages: No page available

10.3892/ijo.2023.5479 | PMID 36660950 Get It

SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors
Huang, Zhenlin , Li, Xiang , Tang, Bo , Li, Hao , Zhang, Jianong , Sun, Rui , Ma, Jian , Pan, Yunqian , Yan, Binyuan , Zhou, Yingke , Ding, Donglin , Yan, Yuqian , Jiménez, Rafael E. , Orme, Jacob J. , Yang, Jinjian , Jia, Zhankui , Sun, Rui , Jimenez, Raphael E , Jin, Xin , Yang, Jinjian , Huang, Rui , Jia, Zhankui , Zhou, Yingke , Yan, Binyuan , Ding, Donglin , Jin, Xin , Huang, Haojie , Sun, Rui

Mayo Clinic

Cancer Research | January 13, 2023 | Volume: 83 | Issue: 6 | Pages: 875-889

10.1158/0008-5472.can-22-0264 | PMID 36637424 Get It

Abstract Retinoblastoma (RB) protein can exert tumor suppressor functions even when it becomes phosphorylated. It is thus essential to understand how phosphorylated RB (p-RB) expression and function are regulated. Here, we demonstrated that RING finger domain protein TRIM28 bound and promoted ubiquitination and degradation of CDK4/6-phosphorylated RB protein. SETDB1, a known TRIM28 binding partner, protected p-RB from degradation through the binding of methylated RB by its Tudor domain independent of its methyltransferase activity. SETDB1 was found to be frequently overexpressed due to gene amplification and positively correlated with p-RB in prostate cancer patient specimens. Inhibition of SETDB1 expression using a gene-specific antisense oligonucleotide (ASO) reduced tumor growth but accelerated RB protein degradation, limiting the therapeutic efficacy. However, coadministration of the CDK4/6 inhibitor palbociclib blocked ASO-induced RB degradation and resulted in a much greater cancer-inhibitory effect than each inhibitor alone both in vitro and in vivo. This study identified CDK4/6-dependent, TRIM28-mediated proteasomal degradation as a mechanism of RB inactivation and reveals SETDB1 as a key inhibitor of this process. Our findings suggest that combined targeting of SETDB1 and CDK4/6 represents a viable approach for the treatment of cancers with SETDB1 gene amplification or overexpression. Significance: The identification of a role for TRIM28 and SETDB1 in regulating CDK4/6-phosphorylated RB stability uncovers a combination strategy using CDK4/6 and SETDB1 inhibition to decrease RB degradation and inhibit cancer growth.
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Dutta, Navnita , Han, Bing , Ciccio, Gina , Cherukuri, Yesesri , Alegria, Victoria R., LaPlant, Betsy, Sher, Taimur , Lanier, Stephanie, Manna, Alak , Heslop, Keisha, Caulfield, Thomas R. , Maldosevic, Emir , Störz, Peter , Asmann, Yan W. , Chanan‐Khan, Asher , Paulus, Aneel , Dutta, Navnita , Han, Bing , LaPlant, Betsy R, Edwards, Brett , Caulfield, Thomas R , Storz, Peter , Asmann, Yan, Chanan-Khan, Asher A., Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek , Edwards, Brett, Manochakian, Rami

Mayo Clinic

Cancers | January 12, 2023 | Volume: 15 | Issue: 2 | Pages: 477

10.3390/cancers15020477 | PMID 36672426 Get It

Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces apoptosis in MM cells. When combined with lenalidomide and dexamethasone (Rd), AT-101 significantly reduced tumor burden in an in vivo xenograft model of MM. These data provided rationale for a phase I/II study to establish the effective dose of AT-101 in combination with Rd (ARd regimen) in relapsed/refractory MM. A total of 10 patients were enrolled, most with high-risk cytogenetics (80%) and prior stem cell transplant (70%). Three patients were lenalidomide-refractory, 2 were bortezomib-refractory and 3 were daratumumab-refractory. The ARd combination was well tolerated with most common grade 3/4 adverse events being cytopenia’s. The overall response rate was 40% and clinical benefit rate was 90%. The median progression free survival was 14.9 months (95% CI 7.1-NE). Patients responsive to ARd showed a decrease in Bcl-2:Bim or Mcl-1:Noxa protein complexes, increased CD8+ T and NK cells and depletion of T and B-regulatory cells. The ARd regimen demonstrated an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM prompting further investigation in additional patients.
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease
Wheelock, Muriah D. , Strain, Jeremy F. , Mansfield, Patricia K. , Tu, Jiaxin Cindy , Tanenbaum, Aaron , Preische, Oliver, Chhatwal, Jasmeer P. , Cash, David M. , Fagan, Anne M. , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Jack, Clifford R. , Xiong, Chengjie , Perrin, Richard J. , Xiong, Chengjie , Morris, John C. , Ances, Beau M. , Eggebrecht, Adam T. , Gordon, Brian A. , Network, the Dominantly Inherited Alzheimer, Adams, Sarah , Araki, Aki, Barthélemy, Nicolas R. , Bechara, Jacob , Berman, Sarah , Bodge, Courtney, Brandon, Susan E. , Brooks, W. K. , Brosch, Jared R. , Buck, Jill , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chrem, Patricio, Chua, Jasmin, Chui, Helena, Cruchaga, Carlos , Day, Gregory S. , Cruz, Chrismary De La, Denner, Darcy, Diffenbacher, Anna, Dincer, Aylin , Donahue, Tamara, Egido, Noelia , Esposito, Bianca, Farlow, Marty, Feldman, Becca , Fitzpatrick, Colleen , Franklin, Erin , Friedrichsen, Nelly, Gardener, Samantha L. , Goate, Alison , Goldberg, Sarah B. , Gonzalez, Alyssa, Gräber‐Sultan, Susanne, Graham, Morgan, Gray, Julia, Gremminger, Emily, Groves, Alex, Haass, Christian , Häsler, Lisa M., Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Igor, Yakushev, Ihara, Ryoko , Ikonomović, Snežana, Ishii, Kenji , Jerome, Gina, Käser, Stephan, Keefe, Sarah , Klunk, William E. , Koudelis, Deb, Kuder-Buletta, Elke, Laske, Christoph , Martinez, Rita, Mason, Neal Scott, Mawuenyega, Kwasi G., Mejia, Arlene, Morenas‐Rodríguez, Estrella , Mori, Hiroshi , Mountz, James M. , Mummery, Cath, Nadkami, Neelesh, Nagamatsu, Akemi, Neimeyer, Katie, Norton, Joanne, Nuscher, Brigitte , Obermüller, Ulricke, Patira, Riddhi , Ping, Lingyan, Ringman, John M. , Salloway, Stephen , Senda, Michio , Seyfried, Nick , Shady, Kristine, Sigurdson, Wendy, Smith, Lori, Snitz, Beth E. , Sohrabi, Hamid R. , Stephens, Sochenda, Taddei, Kevin , Thompson, Sarah , Vöglein, Jonathan , Wang, Peter, Weamer, Elise A., Xu, Jinbin , Cruchaga, Carlos , Fagan, Anne M , Fox, Nick C , Graff-Radford, Neill R , Hassenstab, Jason , Jack, Clifford R , Karch, Celeste M , Xiong, Chengjie , McDade, Eric M , Schofield, Peter R , Xiong, Chengjie , Morris, John C , Bateman, Randall J , Jucker, Mathias , Benzinger, Tammie L S , Ances, Beau M , Eggebrecht, Adam T , Gordon, Brian A , Cruchaga, Carlos , Day, Gregory S , Vöglein, Jonathan , Cash, David M , Goate, Alison M , Berman, Sarah , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, the Dominantly Inherited Alzheimer, Allegri, Ricardo , Brandon, Susan, Brooks, William (Bill), Buck, Jill, Carter, Kathleen, Douglas, Jane, Duong, Duc M , Feldman, Becca, Fitzpatrick, Colleen, Flores, Shaney , Fujii, Hisako , Ghetti, Bernardino , Goldman, Jill , Grilo, Miguel, Hofmann, Anna, Holtzman, David M. , Ikeuchi, Takeshi , Johnson, Erik C. B. , Kasuga, Kensaku , Koeppe, Robert A. , Lee, Jae‐Hong , Levey, Allan I. , Li, Yan , López, Oscar L. , Marsh, Jacob, Martins, Ralph N. , Masters, Colin L. , McCullough, Austin , Niimi, Yoshiki , Noble, James M. , O’Connor, Antoinette , Ping, Lingyan, Renton, Alan , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Smith, Jennifer A. , Thompson, Sarah, Wang, Qing , Xu, Xiong

Mayo Clinic

Brain | January 10, 2023 | Volume: 146 | Issue: 7 | Pages: 2928-2943

10.1093/brain/awac498 | PMID 36625756 Get It

Abstract Neurofilament light chain, a putative measure of neuronal damage, is measurable in blood and CSF and is predictive of cognitive function in individuals with Alzheimer’s disease. There has been limited prior work linking neurofilament light and functional connectivity, and no prior work has investigated neurofilament light associations with functional connectivity in autosomal dominant Alzheimer’s disease. Here, we assessed relationships between blood neurofilament light, cognition, and functional connectivity in a cross-sectional sample of 106 autosomal dominant Alzheimer’s disease mutation carriers and 76 non-carriers. We employed an innovative network-level enrichment analysis approach to assess connectome-wide associations with neurofilament light. Neurofilament light was positively correlated with deterioration of functional connectivity within the default mode network and negatively correlated with connectivity between default mode network and executive control networks, including the cingulo-opercular, salience, and dorsal attention networks. Further, reduced connectivity within the default mode network and between the default mode network and executive control networks was associated with reduced cognitive function. Hierarchical regression analysis revealed that neurofilament levels and functional connectivity within the default mode network and between the default mode network and the dorsal attention network explained significant variance in cognitive composite scores when controlling for age, sex, and education. A mediation analysis demonstrated that functional connectivity within the default mode network and between the default mode network and dorsal attention network partially mediated the relationship between blood neurofilament light levels and cognitive function. Our novel results indicate that blood estimates of neurofilament levels correspond to direct measurements of brain dysfunction, shedding new light on the underlying biological processes of Alzheimer’s disease. Further, we demonstrate how variation within key brain systems can partially mediate the negative effects of heightened total serum neurofilament levels, suggesting potential regions for targeted interventions. Finally, our results lend further evidence that low-cost and minimally invasive blood measurements of neurofilament may be a useful marker of brain functional connectivity and cognitive decline in Alzheimer’s disease.
Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures
Mokgautsi, Ntlotlang , Kuo, Yu‐Cheng, Huang, Yan‐Jiun , Chen, Chien-Hsin, Wu, Alexander T.H. , Huang, Hsu-Shan , Mukhopadhyay, Debabrata , Wu, Alexander T H , Huang, Hsu-Shan , Mukhopadhyay, Debabrata

Mayo Clinic

Cells | January 10, 2023 | Volume: 12 | Issue: 2 | Pages: 266

10.3390/cells12020266 | PMID 36672201 Get It

Colorectal cancer (CRC) is one of the most common cancers, and it frequently metastasizes to the liver and lymph nodes. Despite major advances in treatment modalities, CRC remains a poorly characterized biological malignancy, with high reported cases of deaths globally. Moreover, cancer stem cells (CSCs) and their microenvironment have been widely shown to promote colon cancer development, progression, and metastasis. Therefore, an understanding of the underlying mechanisms that contribute to the maintenance of CSCs and their markers in CRC is crucial in efforts to treat cancer metastasis and develop specific therapeutic targets for augmenting current standard treatments. Herein, we applied computational simulations using bioinformatics to identify potential theranostic markers for CRC. We identified the overexpression of vascular endothelial growth factor-α (VEGFA)/β-catenin/matrix metalloproteinase (MMP)-7/Cluster of Differentiation 44 (CD44) in CRC to be associated with cancer progression, stemness, resistance to therapy, metastasis, and poor clinical outcomes. To further investigate, we explored in silico molecular docking, which revealed potential inhibitory activities of LCC-21 as a potential multitarget small molecule for VEGF-A/CTNNB1/MMP7/CD44 oncogenic signatures, with the highest binding affinities displayed. We validated these finding in vitro and demonstrated that LCC-21 inhibited colony and sphere formation, migration, and invasion, and these results were further confirmed by a Western blot analysis in HCT116 and DLD-1 cells. Thus, the inhibitory effects of LCC-21 on these angiogenic and onco-immunogenic signatures could be of translational relevance as potential CRC biomarkers for early diagnosis.